LONDON and BOSTON, March 7, 2014 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that its Chief Executive Officer, Malcolm Weir, will participate in a panel discussion entitled, "Addressing cognitive deficits across CNS disorders: Potential to improve overall functional outcomes and QoL" (2:45pm-3:45pm CET on 10 March) at BIO-Europe Spring 2014, which takes place in Turin, Italy on 10-12 March.
Dan Grau, Heptares' President will moderate a panel entitled "Pricing and Reimbursement Pressures" at the Boston Biotech BD Conference (1:40pm-2:10pm Eastern time, 25 March) in Boston, MA, USA.
In addition, Dr Weir will give a company presentation at BioCentury Future Leaders in the Biotech Industry in New York City, NY, USA in room 302/303 at 9.30am ET on 28 March.
For a full list of events at which Heptares will be present, please visit http://www.heptares.com
About Heptares Therapeutics
Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our proprietary structure-based drug design technology platform, we have built an exciting pipeline of novel drug candidates with the potential to transform the treatment of serious diseases, including Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com
HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;
StaR is a registered trademark in the EU and Japan.
SOURCE Heptares Therapeutics